In vitro and in vivo application of radiolabeled gastrin-releasing peptide receptor ligands in breast cancer

Journal of Nuclear Medicine

Volumn 56, Issue 5, 2015, Pages 752-757

  Dalm, Simone U ^a   Martens, John W M ^a   Sieuwerts, Anieta M ^a   Van Deurzen, Carolien H M ^a   Koelewijn, Stuart J ^a   De Blois, Erik ^a   Maina, Theodosia ^b   Nock, Berthold A ^b   Brunel, Luc ^c   Fehrentz, Jean Alain ^c   Martinez, Jean ^c   De Jong, Marion ^a   Melis, Marleen ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b INSTITUTE OF NANOSCIENCE AND NANOTECHNOLOGY   (Greece)

^c CNRS   (France)

Author keywords

AMBA; Breast cancer; GRP R; JMV4168; PRS PRRT

Indexed keywords

AMBA INDIUM IN 111; AMBA LUTETIUM LU 177; ESTROGEN RECEPTOR; GASTRIN RELEASING PEPTIDE RECEPTOR; RADIOISOTOPE; RADIOLIGAND; UNCLASSIFIED DRUG; BOMBESIN; BOMBESIN RECEPTOR; INDIUM; LIGAND;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; BREAST CANCER; CONTROLLED STUDY; CYTOTOXICITY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; INTERNALIZATION; ISOTOPE LABELING; MCF 7 CELL LINE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TUMOR VOLUME; TUMOR XENOGRAFT; ANIMAL; BREAST NEOPLASMS; CELL TRANSFORMATION; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC USE; GENE EXPRESSION REGULATION; METABOLISM; PATHOLOGY; TISSUE DISTRIBUTION; TUMOR CELL LINE;

ANIMALS; BOMBESIN; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INDIUM RADIOISOTOPES; ISOTOPE LABELING; LIGANDS; MICE; RECEPTORS, BOMBESIN; TISSUE DISTRIBUTION; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84929500855     PISSN: 01615505     EISSN: 2159662X     Source Type: Journal    
DOI: 10.2967/jnumed.114.153023     Document Type: Article

References (35)

1. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000;406:747-752.
2. Yersal O, Barutca S. Biological subtypes of breast cancer: prognostic and therapeutic implications. World J Clin Oncol. 2014;5:412-424.
3. Garcia EM, Storm ES, Atkinson L, Kenny E, Mitchell LS. Current breast imaging modalities, advances, and impact on breast care. Obstet Gynecol Clin North Am. 2013;40:429-457.
4. Humphrey LL, Helfand M, Chan BK, Woolf SH. Breast cancer screening: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2002;137:347-360.
5. Mahoney MC, Newell MS. Screening MR imaging versus screening ultrasound: pros and cons. Magn Reson Imaging Clin N Am. 2013;21:495-508.
6. Schillaci O, Buscombe JR. Breast scintigraphy today: indications and limitations. Eur J Nucl Med Mol Imaging. 2004;31(suppl 1):S35-S45.
7. Krenning EP, Bakker WH, Breeman WA, et al. Localisation of endocrine-related tumours with radioiodinated analogue of somatostatin. Lancet. 1989;1: 242-244.
8. Kim KW, Krajewski KM, Nishino M, et al. Update on the management of gastroenteropancreatic neuroendocrine tumors with emphasis on the role of imaging. AJR. 2013;201:811-824.
9. Bodei L, Pepe G, Paganelli G. Peptide receptor radionuclide therapy (PRRT) of neuroendocrine tumors with somatostatin analogues. Eur Rev Med Pharmacol Sci. 2010;14:347-351.
10. Reubi C, Gugger M, Waser B. Co-expressed peptide receptors in breast cancer as a molecular basis for in vivo multireceptor tumour targeting. Eur J Nucl Med Mol Imaging. 2002;29:855-862.
11. Gugger M, Reubi JC. Gastrin-releasing peptide receptors in non-neoplastic and neoplastic human breast. Am J Pathol. 1999;155:2067-2076.
12. Halmos G, Wittliff JL, Schally AV. Characterization of bombesin/gastrin-releasing peptide receptors in human breast cancer and their relationship to steroid receptor expression. Cancer Res. 1995;55:280-287.
13. Reubi JC, Maecke HR. Peptide-based probes for cancer imaging. J Nucl Med. 2008;49:1735-1738.
14. 177Lu-labeled GRP-R agonist for systemic radiotherapy of prostate cancer. J Nucl Med. 2006;47:1144-1152.
15. 111In-labeling, and preclinical profile. J Med Chem. 2013;56:2374-2384.
16. 177Lu-labelled methionine-containing regulatory peptides: maintaining radiochemical purity as measured by HPLC. Curr Top Med Chem. 2012;12:2677-2685.
17. De Blois E, Schroeder RJ, De Ridder CA, Van Weerden WM, Breeman WP, De Jong M. Improving radiopeptide pharmacokinetics by adjusting experimental conditions for bombesin receptor-mediated imaging of prostate cancer. Q J Nucl Med Mol Imaging. June 19, 2013 [Epub ahead of print].
18. Riaz M, van Jaarsveld MT, Hollestelle A, et al. miRNA expression profiling of 51 human breast cancer cell lines reveals subtype and driver mutation-specific miRNAs. Breast Cancer Res. 2013;15:R33.
19. Sieuwerts AM, Meijer-van Gelder ME, Timmermans M, et al. How ADAM-9 and ADAM-11 differentially from estrogen receptor predict response to tamoxifen treatment in patients with recurrent breast cancer: a retrospective study. Clin Cancer Res. 2005;11:7311-7321.
20. Droog M, Beelen K, Linn S, Zwart W. Tamoxifen resistance: from bench to bedside. Eur J Pharmacol. 2013;717:47-57.
21. Williams C, Lin CY. Oestrogen receptors in breast cancer: basic mechanisms and clinical implications. Ecancermedicalscience. 2013;7:370.
22. 177Lu using a tumour-targeting folate conjugate. Eur J Nucl Med Mol Imaging. 2014;41:476-485.
23. Wild D, Fani M, Fischer R, et al. Comparison of somatostatin receptor agonist and antagonist for peptide receptor radionuclide therapy: a pilot study. J Nucl Med. 2014;55:1248-1252.
24. 177Lu-AMBA bombesin analogue in hormone refractory prostate cancer patients: a phase I escalation study with single-cycle administrations [abstract]. Eur J Nucl Med Mol Imaging. 2007;34(suppl 2):S221.
25. Cescato R, Maina T, Nock B, et al. Bombesin receptor antagonists may be preferable to agonists for tumor targeting. J Nucl Med. 2008;49:318-326.
26. Suda H, Aoyagi T, Takeuchi T, Umezawa H. Letter: a thermolysin inhibitor produced by actinomycetes - phospholamidon. J Antibiot (Tokyo). 1973;26:621-623.
27. Nock BA, Maina T, Krenning EP, de Jong M. "To serve and protect": enzyme inhibitors as radiopeptide escorts promote tumor targeting. JNuclMed.2014;55:121-127.
28. Parry JJ, Andrews R, Rogers BE. MicroPET imaging of breast cancer using radiolabeled bombesin analogs targeting the gastrin-releasing peptide receptor. Breast Cancer Res Treat. 2007;101:175-183.
29. 99mTc BN1). In Vivo. 2005;19:1071-1076.
30. Soluri A, Scopinaro F, De Vincentis G, et al. 99MTC [13LEU] bombesin and a new gamma camera, the imaging probe, are able to guide mammotome breast biopsy. Anticancer Res. 2003;23:2139-2142.
31. Van de Wiele C, Phonteyne P, Pauwels P, et al. Gastrin-releasing peptide receptor imaging in human breast carcinoma versus immunohistochemistry. J Nucl Med. 2008;49:260-264.
32. 99mTc-bombesin scintigraphy for differentiation of malignant from benign breast lesions. Nucl Med Commun. 2014;35:620-625.
33. 68Galabelled GRP-receptor antagonist, "Sarabesin 3": first clinical data in patients with prostate and breast cancer [abstract]. J Nucl Med. 2013;54(suppl 2):280.
34. Dumont RA, Tamma M, Braun F, et al. Targeted radiotherapy of prostate cancer with a gastrin-releasing peptide receptor antagonist is effective as monotherapy and in combination with rapamycin. J Nucl Med. 2013;54:762-769.
35. Stewart FA, Akleyev AV, Hauer-Jensen M, et al. ICRP publication 118: ICRP statement on tissue reactions and early and late effects of radiation in normal tissues and organs - threshold doses for tissue reactions in a radiation protection context. Ann ICRP. 2012;41:1-322.